Msi H Dmmr Gastric Cancer clinical trials

Explore recruiting msi h dmmr gastric cancer clinical trials.

Recruiting msi h dmmr gastric cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Msi H Dmmr Gastric Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

CIME - Combination of Immune checkpoint in locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas : A multicenter, randomised, comparative, open-label Phase III aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combination of Immune checkpoint inhibitors (botensilimab + balstilimab) versus the standard of care (FOLFOX/XELOX + nivolumab)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Open label, non-randomized, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) as a part of combination therapy in participants with locally advanced and unresectable or metastatic MSI-H/dMMR gastro-esophageal junction/gastric cancer

Spain, Italy, Belgium, France, Austria, Denmark +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Msi H Dmmr Gastric Cancer trials by city

Msi H Dmmr Gastric Cancer clinical trials

Recruiting msi h dmmr gastric cancer studies right now

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

A Beta-only IL-2 ImmunoTherapY Study

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Also recruiting in Europe

Open label, non-randomized, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) as a part of combination therapy in participants with locally advanced and unresectable or metastatic MSI-H/dMMR gastro-esophageal junction/gastric cancer

Msi H Dmmr Gastric Cancer trials by city

Other conditions